1. Home
  2. BKH vs CRSP Comparison

BKH vs CRSP Comparison

Compare BKH & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Black Hills Corporation

BKH

Black Hills Corporation

HOLD

Current Price

$73.89

Market Cap

5.5B

Sector

Utilities

ML Signal

HOLD

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$55.05

Market Cap

4.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BKH
CRSP
Founded
1941
2013
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
4.9B
IPO Year
2001
2016

Fundamental Metrics

Financial Performance
Metric
BKH
CRSP
Price
$73.89
$55.05
Analyst Decision
Buy
Buy
Analyst Count
5
17
Target Price
$77.80
$70.29
AVG Volume (30 Days)
825.6K
1.6M
Earning Date
05-06-2026
05-11-2026
Dividend Yield
3.78%
N/A
EPS Growth
1.79
N/A
EPS
3.98
N/A
Revenue
$2,310,000,000.00
$289,590,000.00
Revenue This Year
$4.98
$807.72
Revenue Next Year
$3.92
$172.52
P/E Ratio
$18.57
N/A
Revenue Growth
8.57
9169.85
52 Week Low
$55.49
$34.12
52 Week High
$78.69
$78.48

Technical Indicators

Market Signals
Indicator
BKH
CRSP
Relative Strength Index (RSI) 49.48 55.97
Support Level $71.11 $50.91
Resistance Level $75.55 $55.30
Average True Range (ATR) 1.64 2.78
MACD -0.20 -0.08
Stochastic Oscillator 38.98 60.35

Price Performance

Historical Comparison
BKH
CRSP

About BKH Black Hills Corporation

Black Hills Corp is a U.S.-based energy company that operates through its Electric Utilities and Gas Utilities segment. These segments operate in states in the Midwest and mountain regions in the U.S. The company's customers include residential, commercial, industrial, and municipal consumers. These customers are residential. Black Hills derives the majority of its revenue from its utility business group, specifically from gas utilities.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: